Advisory Board January 22, 2025

CMS last week announced the next 15 drugs to be included in Medicare price negotiations, a list that includes the diabetes and weight-loss drugs Ozempic and Wegovy

4 things leaders need to know about high-cost drugs

CMS announces next 15 drugs for price negotiations

The list of drugs includes:

  • Ozempic, Rybelsus, and Wegovy for Type 2 diabetes and weight loss
  • Trelegy Ellipta, an asthma treatment
  • Xtandi, for prostate cancer
  • Pomalyst, a chemotherapy drug
  • Ibrance, a breast cancer drug
  • Ofev, for idiopathic pulmonary fibrosis
  • Linzess, a chronic constipation drug
  • Calquence, a cancer drug
  • Austedo and Austedo XR for Huntington’s disease
  • Breo Ellipta, a COPD drug
  • Tradjenta, a diabetes drug
  • Xifaxan, for diarrhea and irritable bowel syndrome
  • Vraylar, an antipsychotic drug
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Musk's team accesses Medicare, Medicaid records
Musk’s DOGE Reportedly Digging Into Medicare Payment System
DOGE turns focus to CMS spending, contracts, news report says
Are Medicare Fee Schedules Appropriate For Commercial Populations?
Medicare's 2025 physician pay cut, explained

Share This Article